image of a green circle Annotated and expert reviewed. Please contact us if you can help with updates. 

D3 receptor

Family: Dopamine receptors

Contents:
Gene and Protein Information
Previous and Unofficial Names
Database Links
Selected 3D Structures
Agonists
Antagonists
Transduction Mechanisms
Tissue Distribution
Expression Datasets
Functional Assays
Physiological Functions
Physiological Consequences of Altering Gene Expression
Phenotypes, Alleles and Disease Models
Clinically-Relevant Mutations and Pathophysiology
Biologically Significant Variants
General Comments
References
Gene and Protein Information
class A G protein-coupled receptor
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 7 400 3q13.3 DRD3 dopamine receptor D3 33
Mouse 7 446 16 B4 Drd3 dopamine receptor D3 91
Rat 7 446 11q21 Drd3 dopamine receptor D3 27
Previous and Unofficial Names
D3 receptor
D(3) dopamine receptor
dopamine D3 receptor
dopamine receptor D3
dopaminergic receptor D3
D3R
Database Links
ChEMBL Target 130 (Hs), 11429 (Mm), 11430 (Rn)
DrugBank Target 638 (Hs)
Ensembl ENSG00000151577 (Hs), ENSMUSG00000022705 (Mm), ENSRNOG00000026772 (Rn)
Entrez Gene 1814 (Hs), 13490 (Mm), 29238 (Rn)
GeneCards DRD3 (Hs)
GenitoUrinary Development Molecular Anatomy Project Drd3 (Mm)
HomoloGene 623 (Hs)
Human Protein Reference Database 00540 (Hs)
InterPro P35462 (Hs), P30728 (Mm), P19020 (Rn)
KEGG Gene hsa:1814 (Hs), mmu:13490 (Mm), rno:29238 (Rn)
OMIM 126451 (Hs)
Orphanet Gene ORPHA121179 (Hs)
PharmGKB Gene PA27479 (Hs)
PhosphoSitePlus P35462 (Hs), P30728 (Mm), P19020 (Rn)
Protein Ontology (PRO) PRO:000001178 (Hs)
RefSeq Nucleotide NM_000796 (Hs), NM_007877 (Mm), NM_017140 (Rn)
RefSeq Protein NP_000787 (Hs), NP_031903 (Mm), NP_058836 (Rn)
TreeFam ENSG00000151577 (Hs), ENSMUSG00000022705 (Mm), ENSRNOG00000026772 (Rn)
UniGene Hs. 121478 (Hs)
UniProt P35462 (Hs), P30728 (Mm), P19020 (Rn)
Wikipedia D3 receptor
Dopamine receptors
Selected 3D Structures
Image of receptor 3D structure from RCSB PDB
Description:  D3dopamine receptor (lysozyme chimera)
PDB Id:  3PBL
Ligand:  ED-71
Resolution:  2.89Å
Species:  Human
References: 
Search for other structures on the PDB
Search by keyword: Dopamine receptors D3 receptor Search by accession number: P19020, P35462, P30728
Natural/Endogenous Ligand(s)
dopamine
Agonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]7-OH-DPAT Hs Agonist 9.6 pKd 82
[3H]PD128907 Hs Agonist 9.0 pKd 3
lisuride Hs Partial agonist 9.6 pKi 68
cabergoline Hs Partial agonist 9.1 pKi 68
terguride Hs Partial agonist 9.0 pKi 68
roxindole Hs Partial agonist 8.9 pKi 68
(-)-N-porphynorapomorphine Hs Full agonist 8.4 – 8.7 pKi 28,85
pramipexole Hs Full agonist 8.4 – 8.7 pKi 64,85
pergolide Hs Partial agonist 8.3 pKi 68
7-OH-DPAT Hs Full agonist 7.1 – 8.4 pKi 12,18,28,57
7-trans-OH-PIPAT Hs Full agonist 7.7 pKi 18
apomorphine Rn Partial agonist 7.7 pKi 91
bromocriptine Hs Partial agonist 7.1 – 8.2 pKi 28,68,85
PD 128907 Hs Full agonist 7.6 – 7.7 pKi 79,85
quinpirole Rn Full agonist 7.3 – 7.8 pKi 12,91
quinelorane Hs Full agonist 7.2 – 7.4 pKi 69,90
quinpirole Hs Full agonist 6.4 – 8.0 pKi 12,64,69,90-91
bromocriptine Rn Full agonist 7.1 pKi 91
dopamine Hs Full agonist 6.4 – 7.3 pKi 12,28,85,91
apomorphine Hs Partial agonist 6.1 – 7.6 pKi 12,28,68,85,90
piribedil Hs Partial agonist 6.6 pKi 68
View species-specific agonist tables
Antagonists
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Affinity Units Reference
[3H]spiperone Rn Antagonist 10.5 pKd 105
[3H]nemonapride Hs Antagonist 10.3 pKd 58
S33084 Hs Antagonist 9.6 pKi 67
nemonapride Hs Antagonist 9.2 – 9.3 pKi 57,98
spiperone Hs Antagonist 9.2 pKi 91
eticlopride Hs Antagonist 8.8 pKi 57,98
nafadotride Hs Antagonist 8.5 pKi 86
cis flupentixol Hs Antagonist 7.7 – 8.6 pKi 28
SB 277011-A Hs Antagonist 8.0 pKi 80
raclopride Hs Antagonist 7.9 pKi 69
pimozide Hs Antagonist 7.0 – 8.6 pKi 28,90
haloperidol Hs Antagonist 7.5 – 8.0 pKi 28,90
raclopride Rn Antagonist 7.5 pKi 91
(-)-sulpiride Hs Antagonist 6.9 – 8.1 pKi 12,28,59,90,98
amisulpride Rn Antagonist 7.4 pKi 91
(+)-butaclamol Rn Antagonist 7.3 – 7.5 pKi 12
pimozide Rn Antagonist 7.4 pKi 91
(+)-butaclamol Hs Antagonist 6.7 – 8.0 pKi 28,79,98
chlorpromazine Hs Antagonist 7.2 – 7.5 pKi 28,90
domperidone Hs Antagonist 7.1 – 7.6 pKi 28,90
chlorpromazine Rn Antagonist 7.2 pKi 91
(+)-UH232 Hs Antagonist 7.0 – 7.4 pKi 28,91
domperidone Rn Antagonist 7.0 pKi 91
haloperidol Rn Antagonist 7.0 pKi 91
risperidone Hs Antagonist 7.0 pKi 69
(+)-UH232 Rn Antagonist 7.0 pKi 91
(+)-S-14297 Hs Antagonist 6.9 pKi 69
(+)-sulpiride Rn Antagonist 6.4 pKi 91
(+)-AJ76 Hs Antagonist 5.9 – 6.2 pKi 69,90
(+)-sulpiride Hs Antagonist 5.8 – 6.3 pKi 28,59
(+)-AJ76 Rn Antagonist 6.0 pKi 91
clozapine Hs Antagonist 5.2 – 6.3 pKi 28,90
clozapine Rn Antagonist 5.7 pKi 91
trans flupenthixol Hs Antagonist 5.3 – 5.9 pKi 28
View species-specific antagonist tables

Explore drug-target interactions for this set of compounds using iPHACE

Primary Transduction Mechanisms
Transducer Effector/Response
Gi/Go family Adenylate cyclase inhibition
Potassium channel
References:  17,55,77-78,88
Tissue Distribution
Ventral striatum/nucleus accumbens > neostriatum, cerebral cortex, cerebellar cortex.
Species:  Human
Technique:  Autoradiography.
References:  36,46
Brain: nucleus accumbens and islands of Calleja.
Species:  Human
Technique:  in situ hybridization.
References:  47
Brain: islands of Cajella, olafactory bulb, pituitary intermediate lobe > nucleus accumbens, molecular layer of the vestibulocerebellum, substantia nigra pars compacta.
Species:  Rat
Technique:  Autoradiography and in situ hybridization.
References:  6,30,48,53,56,75,81
Accumbens nucleus, islands of Calleja, bed nucleus of the stria terminalis, hippocampus, mammillary nuclei, substantia nigra.
Species:  Rat
Technique:  in situ hybridization.
References:  8
Expression Datasets

Click here to show/hide data

Log average relative transcript abundance in mouse tissues measured by qPCR from Regard, J.B., Sato, I.T., and Coughlin, S.R. (2008). Anatomical profiling of G protein-coupled receptor expression. Cell, 135(3): 561-71. [PMID:18984166] [Raw data: website]

There should be a chart of expression data here, you may need to enable JavaScript!
Functional Assays
Measurement of adenylyl cyclase activity in CHO cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  CHO cells.
Response measured:  Inhibition of adenylyl cyclase.
References:  17
Measurement of extracellular acidification rates in CHO cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  CHO cells.
Response measured:  Increase in extracellular acidification rates.
References:  17
Measurement of extracellular acidification and D3 receptor membrane density in C6 glioma cells transfected with the rat D3 receptor.
Species:  Rat
Tissue:  C6 glioma cells.
Response measured:  Increase in extracellular acidification rate and receptor density.
References:  21
Measurement of c-fos activation and increased mitogenesis in neuroblastoma-glioma hybrid cells (NG108-15) transfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Increase in c-fos activation and mitogenesis.
References:  77
Measurement of cAMP accumulation in cultured Xenopus laevis melanophores transfected with the human D3 receptor.
Species:  Human
Tissue:  Cultured Xenopus laevis melanophores.
Response measured:  Inhibition of cAMP accumulation.
References:  78
Measurement of whole-cell potassium current in NG108-15 cells tranfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Reduction of peak whole-cell potassium current.
References:  55
Measurement of activation of GIRK1 in Xenopus oocytes transfected with the human D3 receptor.
Species:  Human
Tissue:  Xenopus oocytes.
Response measured:  Activation of GIRK1.
References:  101
Measurement of mitogenesis in NG108-15 cells transfected with the human D3 receptor.
Species:  Human
Tissue:  NG108-15 cells.
Response measured:  Increase in mitogenesis.
References:  85
Measurement of melanocyte aggregation in Xenopus melanocytes transfected with the human D3 receptor.
Species:  Human
Tissue:  Xenopus melanocytes.
Response measured:  Stimulation of melanocyte aggregation.
References:  11,79
Measurement of extracellular acidification in CHO cells transfected with the human D3 receptor.
Species:  Human
Tissue:  CHO cells.
Response measured:  Increase in extracellular acidification.
References:  11
Measurement of activation of an 85 pS K+ channel known to be activated by dopamine and the "D2-like" agonist quinpirole.
Species:  Human
Tissue:  Freshly dissociated rat caudate-putamen neurons.
Response measured:  Activation of K+ channel.
References:  54
Measurement of dopamine release from a mesencephalic clonal cell line transfected with the D3 receptor.
Species:  Human
Tissue:  Neuronal mesencephalic MN9D cells.
Response measured:  Inhibition of dopamine release.
References:  97
Measurement of K+-stimulated tyrosine hydroxylase activity in D3 receptor-expressing MN9D cells.
Species:  Human
Tissue:  MN9D cells
Response measured:  Decrease in K+-stimulated tyrosine hydroxylase activity.
References:  73
Measurement of cAMP levels in HEK 293 cells transfected with the human D3 receptor.
Species:  Human
Tissue:  HEK 293 cells.
Response measured:  Inhibition of cAMP accumulation.
References:  61
Measurement of Cl- currents in Xenopus oocytes transfected with murine D3L and D3S receptors.
Species:  Mouse
Tissue:  Xenopus oocytes.
Response measured:  Stimulation of Cl- influx.
References:  89
Physiological Functions
Inhibition of dopamine release.
Species:  Rat
Tissue:  In vivo.
References:  24,79
Stimulation of the D3 receptor produces an aversive effect in a conditioned place-preference paradigm.
Species:  Rat
Tissue:  In vivo.
References:  16
Activation increases cell division.
Species:  Rat
Tissue:  CHO cells.
References:  17
Inhibition of locomotor activity.
Species:  Rat
Tissue:  In vivo.
References:  2,23,25,31,38,40,42,52,62,79,86,95-96,99-100
Modulation of motor activity.
Species:  Mouse
Tissue:  In vivo.
References:  93
Stimulation of yawning and hypothermia.
Species:  Rat
Tissue:  In vivo.
References:  2,24,40,45,65-66,69
Modulation of sniffing behaviour.
Species:  Rat
Tissue:  In vivo.
References:  23
Modulation of penile erection and ejaculatory behaviour.
Species:  Rat
Tissue:  In vivo.
References:  14,45
Modulation of self-administration of cocaine.
Species:  Rat
Tissue:  In vivo.
References:  13
Modulation of self-stimulation of the ventral tegmental area.
Species:  Rat
Tissue:  In vivo.
References:  25
Modulation of reinforcing effects of cocaine and d-amphetamine.
Species:  Rat
Tissue:  In vivo.
References:  41
Stimulation of the D3 receptor decreases the rate of food-reinforced responding in a fixed-ratio operant paradigm.
Species:  Rat
Tissue:  In vivo.
References:  84
Hyperpolarization of neurons and inhibition of cell firing.
Species:  Rat
Tissue:  Substantia nigra pars compacta and ventral tegmental area of rat brain slices.
References:  9
A D3 agonist with relative selectivity for the dopamine D3 receptor, inhibits the firing of both A9 and A10 dopamine neurons and causes current-dependent inhibitions of spontaneously active or glutamate-driven caudate-putamen and nucleus accumbens neurons.
Species:  Rat
Tissue:  Substantia nigra pars compacta and ventral tegmental area dopamine neurons, and caudate-putamen and nucleus accumbens neurons in vivo.
References:  54
Systemic administration of a D3 receptor agonist decreases extracellular dopamine and 3,4-dihydroxyphenylacetic acid (DOPAC) levels in the nucleus accumbens and dopaminergic neuronal activity in the ventral tegmental area.
Species:  Rat
Tissue:  In vivo.
References:  26
A D3 agonist inhibits substantia nigra pars compacta dopamine single cell firing.
Species:  Rat
Tissue:  In vivo.
References:  44
A D3 agonist inhibits ventral tagmental area dopamine single cell firing.
Species:  Rat
Tissue:  In vivo.
References:  51
Administration of a D3 agonist to freely moving rats decreases dialysate levels of dopamine in the nucleus accumbens.
Species:  Rat
Tissue:  In vivo.
References:  83
Application of a D3 receptor agonist reduces electrically-evoked dopamine release from the nucleus accumbens and striatum.
Species:  Rat
Tissue:  Nucleus accumbens and striatal slices.
References:  104
Modulation of dopamine synthesis.
Species:  Rat
Tissue:  In vivo.
References:  4,29,34,79
Physiological Consequences of Altering Gene Expression
D3 receptor knockout mice exhibit altered circadian pattern in spinal dopamine synthesis.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  19
D3 receptor knockout mice exhibit renin-dependent hypertension.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  5
D3 receptor knockout mice exhibit aggravation of the development of physical dependence on ethanol.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  72
D3 receptor knockout mice exhibit increased gene expression in striatal neurons following acute administration of cocaine.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  15
D3 receptor knockout mice exhibit higher basal levels of extracellular dopamine compared to the wild-type.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  20,37
D3 receptor knockout mice display enhanced hyperactivity when compared to the wild-type, although these effects may be limited.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  1,7,103
D3 receptor knockout mice display a transient increase in activity in a novel environment compared with wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  43,102
D3 receptor knockout mice exhibit increased behavioural sensitivity to combined injections of D1 and D2 class receptor agonists, cocaine and amphetamine.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  103
D3 receptor knockout mice exhibit reduced anxiety.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  94
D3 receptor knockout mice exhibit increased morphine-induced rewarding effects and potentiation of morphine-induced hyperlocomotion.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  71
D3 receptor knockout mice display similar effects (reward/intake) of ethanol as wild-type mice.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  10
D3 receptor knockout mice exhibit increased D1/D2 receptor-mediated intracellular signalling.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  70
D3 receptor knockout mice exhibit increased adiposity induced by a high-fat diet.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  63
D3 receptor knockout mice exhibit neuroadaptive changes which support the role of D3 receptors as autoreceptors.
Species:  Mouse
Tissue: 
Technique:  Gene targeting in embryonic stem cells.
References:  50
D3 receptor knockout mice display increased susceptibility to cocaine addition
Species:  Mouse
Tissue: 
Technique:  Gene knockout
References:  92
Phenotypes, Alleles and Disease Models Mouse data from MGI

Click here to show/hide data

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
+|Cm|Drd3tm1Stl Cm/+,Drd3tm1Stl/Drd3tm1Stl
involves: 101/H * 129S2/SvPas * C3H/HeH * C3H/HeSn * C57BL/6J		 MGI:88424  MGI:94925  MP:0009748 abnormal behavioral response to addictive substance PMID: 19840852 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0001454 abnormal cued conditioning behavior PMID: 9354330 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001905 abnormal dopamine level PMID: 10391470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0005449 abnormal food intake PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0006001 abnormal intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0006003 abnormal large intestinal transit time PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3+|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3+
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2+|Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2+,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001392 abnormal locomotor activity PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0001666 abnormal nutrient absorption PMID: 16525059 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0000676 abnormal water content PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001262 decreased body weight PMID: 10391470 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0001262 decreased body weight PMID: 16525059 
Drd3tm1Rmw Drd3tm1Rmw/Drd3tm1Rmw
involves: 129P2/OlaHsd		 MGI:94925  MP:0005643 decreased dopamine level PMID: 12044470 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001442 decreased grooming behavior PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001442 decreased grooming behavior PMID: 8700864 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0001505 hunched posture PMID: 10391470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0001399 hyperactivity PMID: 9354330 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001399 hyperactivity PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001399 hyperactivity PMID: 8700864 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0005669 increased circulating leptin level PMID: 15084447 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0003867 increased defecation PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0003911 increased drinking behavior PMID: 16525059 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
B6.Cg-Drd2 Drd3		 MGI:94924  MGI:94925  MP:0003909 increased eating behavior PMID: 16525059 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0001415 increased exploration in new environment PMID: 9354330 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001415 increased exploration in new environment PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0001415 increased exploration in new environment PMID: 8700864 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0005458 increased percent body fat PMID: 15084447 
Drd3tm1Rmw Drd3tm1Rmw/Drd3tm1Rmw
involves: 129P2/OlaHsd		 MGI:94925  MP:0001409 increased stereotypic behavior PMID: 12044470 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0005455 increased susceptibility to weight gain PMID: 15084447 
Drd3tm1Stl Drd3tm1Stl/Drd3tm1Stl
involves: 129S2/SvPas * C57BL/6		 MGI:94925  MP:0010024 increased total body fat amount PMID: 15084447 
Drd3tm1Dac Drd3tm1Dac/Drd3tm1Dac
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0002574 increased vertical activity PMID: 8700864 
Drd3+|Drd3tm1Dac Drd3tm1Dac/Drd3+
involves: 129S4/SvJae * C57BL/6		 MGI:94925  MP:0002574 increased vertical activity PMID: 8700864 
Drd2tm1Schm|Drd3tm1Schm Drd2tm1Schm/Drd2tm1Schm,Drd3tm1Schm/Drd3tm1Schm
involves: 129S1/Sv * 129X1/SvJ * C57BL/6		 MGI:94924  MGI:94925  MP:0002082 postnatal lethality PMID: 10391470 
Clinically-Relevant Mutations and Pathophysiology
Disease:  Hereditary essential tremor, 1
OMIM:  190300
Orphanet:  862
References: 
Mutations not determined
Biologically Significant Variants
The BalI restriction fragment length polymorphism (corresponding to a point mutation in the 1st exon and resulting in a serine-to-glycine substitution in the N-terminal extracellular domain of the receptor) has been associated with schizophrenia.
Type:  Point mutation.
Species:  Human
References:  22,39,60
The BalI polymorphism has been associated with bipolar disorder.
Type:  Point mutation.
Species:  Human
References:  74
General Comments
Alternative splicing leads to a 425aa isoform in mouse[27] and several shorter presumably inactive isoforms in rat[32] and human[87]. Two polymorphic variants [Ser9] and [Gly9] in human[49]. The organization of the coding sequence of the human gene has been established[35]. Anti-psychotic drugs display closely similar or slightly lower antagonist affinity at D3 compared to D2 receptors. S(+)14297, initially reported as a D3 receptor antagonist[69] displays full agonist activity in two functional assays[76].

REFERENCES

Show »

1. Accili, D., Fishburn, C. S., Drago, J., Steiner, H., Lachowicz, J. E., Park, B. H., Gauda, E B., Lee, E. J., Cool, M. H., Sibley, D. R., Gerfen, C. R., Westphal, H. and Fuchs, S. (1996) A targeted mutation of the D3 receptor gene is associated with hyperactivity in mice. Proc. Natl. Acad. Sci. U.S.A., 93: 1945-1949. [PMID:8700864]

2. Ahlenius, S. and Salmi, P. (1994) Behavioral and biochemical effects of the dopamine D3 receptor-selective ligand, 7-OH-DPAT, in the normal and the reserpine-treated rat. Eur J Pharmacol, 260: 177-181. [PMID:7988642]

3. Akunne, HC; Towers, P; Ellis, GJ; Dijkstra, D; Wikström, H; Heffner, TG; Wise, LD; Pugsley, TA. (1995) Characterization of binding of [3H]PD 128907, a selective dopamine D3 receptor agonist ligand, to CHO-K1 cells. Life Sci., 57 (15): 1401-10. [PMID:7674830]

4. Aretha, C. W., Sinha, A. and Galloway, M. P. (1995) Dopamine D3-preferring ligands act at synthesis modulating autoreceptors. J Pharmacol Exp Ther, 274: 609-613. [PMID:7636720]

5. Asico, L. D., Ladines, C., Fuchs, S., Accili, D., Carey, R. M., Semeraro, C., Pocchiari, F., Felder, R. A, Eisner, G and Jose, P. A. (1998) Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension. J. Clin. Invest., 102: 493-498. [PMID:9691085]

6. Booze, R. M. and Wallace, D. R. (1995) Dopamine D2 and D3 receptors in the rat striatum and nucleus accumbens: use of 7-OH-DPAT and [125I]-iodosulpride. Synapse, 19: 1-13. [PMID:7709338]

7. Boulay, D., Depoortere, R., Rostene, W., Perrault, G. and Sanger, D. J. (1999) Dopamine D3 receptor agonists produce similar decreases in body temperature and locomotor activity in D3 knock-out and wild-type mice. Neuropharmacology, 38: 555-565. [PMID:10221759]

8. Bouthenet, M.-L., Souil, E., Martres, M.-P., Sokoloff, P., Giros, B. and Schwartz, J.-C. (1991) Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with D2 receptor mRNA. Brain Res., 564: 203-219. [PMID:1839781]

9. Bowery, B., Rothwell, L. A. and Seabrook, G. R. (1994) Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental area. Br J Pharmacol, 112: 873-880. [PMID:7921615]

10. Boyce-Rustay, J. M. and Risinger, F. O. (2003) Dopamine D3 receptor knockout mice and the motivational effects of ethanol. Pharmacol Biochem Behav, 75: 373-379. [PMID:12873629]

11. Boyfield, I., Winn, F. and Coldwell, M. (1996) Comparison of agonist potencies at human dopamine D2 and D3 receptors, expressed in the same cell line, using the Cytosensor Microphysiometer. Biochem Soc Trans, 24: 57S-57S. [PMID:8674731]

12. Burris, K. D., Pacheco, M. A., Filtz, T. M., Kung, M. P., Kung, H. F. and Molinoff, P. B. (1995) Lack of discrimination by agonists for D2 and D3 dopamine receptors. Neuropsychopharmacology, 12: 335-345. [PMID:7576010]

13. Caine, S. B. and Koob, G. F. (1993) Modulation of cocaine self-administration in the rat through D-3 dopamine receptors. Science, 260: 1814-1816. [PMID:8099761]

14. Carlsson, A., Lindqvist, M. and Magnusson, M. (1957) 3,4-Dihydroxyphenylalanine and 5-hydroxytryptophan as reserpine antagonists. Nature, 180: 1200-. [PMID:13483658]

15. Carta, A. R., Gerfen, C. R. and Steiner, H. (2000) Cocaine effects on gene regulation in the striatum and behavior: increased sensitivity in D3 dopamine receptor-deficient mice. Neuroreport, 11: 2395-2399. [PMID:10943692]

16. Chaperon, F. and Thiébot, M. H. (1996) Effects of dopaminergic D3-receptor-preferring ligands on the acquisition of place conditioning in rats. Behav Pharmacol, 7: 105-109. [PMID:11224401]

17. Chio, C. L., Lajiness, M. E. and Huff, R. M. (1994) Activation of heterologously expressed D3 dopamine receptors: comparison with D2 dopamine receptors. Mol Pharmacol, 45: 51-60. [PMID:8302280]

18. Chumpradit, S., Kung, M. P., Vessotskie, J., Foulon, C., Mu, M. and Kung, H. F. (1994) Iodinated 2-aminotetralins and 3-amino-1-benzopyrans: ligands for dopamine D2 and D3 receptors. J Med Chem, 37: 4245-4250. [PMID:7990123]

19. Clemens, S., Sawchuk, M. A. and Hochman, S. (2005) Reversal of the circadian expression of tyrosine-hydroxylase but not nitric oxide synthase levels in the spinal cord of dopamine D3 receptor knockout mice. Neuroscience, 133: 353-357. [PMID:15878801]

20. Cooper, D. C., Loeltzow, T. E., Xu, M., Tonegawa, S., White, F. J. and Wolf, M. E. (1996) Regulations of dopamine release and synthesis in dopamine D3R receptor knockout mice. (Abstract) Soc. Neurosci. Abst., 22: 1319-.

21. Cox, B. A., Rosser, M. P., Kozlowski, M. R., Duwe, K. M., Neve, R. L. and Neve, K. A. (1995) Regulation and functional characterization of a rat recombinant dopamine D3 receptor. Synapse, 21: 1-9. [PMID:8525456]

22. Crocq, M. A., Mant, R., Asherson, P., Williams, J., Hode, Y., Mayerova, A., Collier, D., Lannfelt, L., Sokoloff, P. and Schwartz, J. C. (1992) Association between schizophrenia and homozygosity at the dopamine D3 receptor gene. J Med Genet, 29: 858-860. [PMID:1362221]

23. Daly, S. A. and Waddington, J. L. (1993) Behavioural effects of the putative D-3 dopamine receptor agonist 7-OH-DPAT in relation to other "D-2-like" agonists. Neuropharmacology, 32: 509-510. [PMID:8321432]

24. Damsma, G., Bottema, T., Westerink, B. H., Tepper, P. G., Dijkstra, D., Pugsley, T. A., MacKenzie, R. G., Heffner, T. G. and Wikström, H. (1993) Pharmacological aspects of R-(+)-7-OH-DPAT, a putative dopamine D3 receptor ligand. Eur J Pharmacol, 249: R9-10. [PMID:8287911]

25. Depoortere, R., Perrault, G. and Sanger, D. J. (1996) Behavioural effects in the rat of the putative dopamine D3 receptor agonist 7-OH-DPAT: comparison with quinpirole and apomorphine. Psychopharmacology (Berl), 124: 231-240. [PMID:8740044]

26. Devoto, P., Collu, M., Muntoni, A. L., Pistis, M., Serra, G., Gessa, G. L. and Diana, M. (1995) Biochemical and electrophysiological effects of 7-OH-DPAT on the mesolimbic dopaminergic system. Synapse, 20: 153-155. [PMID:7570345]

27. Fishburn, C., Bellili, D., David, C., Carmon, S. and Fuchs, S. (1993) A novel short isoform of the D3 dopamine receptor generated by alternative splicing in the third cytoplasmic loop. J. Biol. Chem., 268: 5872-5878. [PMID:8449953]

28. Freedman, S. B., Patel, S., Marwood, R., Emms, F., Seabrook, G. R., Knowles, M. R. and McAllister, G. (1994) Expression and pharmacological characterization of the human D3 dopamine receptor. J Pharmacol Exp Ther, 268: 417-426. [PMID:8301582]

29. Gainetdinov, R. R., Sotnikova, T. D., Grekhova, T. V. and Rayevsky, K. S. (1996) In vivo evidence for preferential role of dopamine D3 receptor in the presynaptic regulation of dopamine release but not synthesis. Eur J Pharmacol, 308: 261-269. [PMID:8858296]

30. Gehlert, D. R., Gackenheimer, S. L., Seeman, P. and Schaus, J. (1992) Autoradiographic localization of [3H]quinpirole binding to dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol, 211: 189-194. [PMID:1351846]

31. Gilbert, D. B. and Cooper, S. J. (1995) 7-OH-DPAT injected into the accumbens reduces locomotion and sucrose ingestion: D3 autoreceptor-mediated effects?. Pharmacol Biochem Behav, 52: 275-280. [PMID:8577791]

32. Giros, B., Martres, M. P., Pilon, C., Sokoloff, P. and Schwartz, J. C. (1991) Shorter variants of the D3 dopamine receptor produced through various patterns of alternative splicing. Biochem. Biophys. Res. Commun., 176: 1584-1592. [PMID:2039532]

33. Giros, B., Martres, M.-P., Sokoloff, P. and Schwartz, J.-C. (1990) cDNA cloning of the human dopaminergic D3 receptor and chromosome identification. C. R. Acad. Sci. III, 311: 501-508. [PMID:2129115]

34. Gobert, A., Rivet, J. M., Audinot, V., Cistarelli, L., Spedding, M., Vian, J., Peglion, J. L. and Millan, M. J. (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: II. Both D2 and "silent" D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostriatal pathways. J Pharmacol Exp Ther, 275: 899-913. [PMID:7473181]

35. Griffon, N., Crocq, M. A., Pilon, C., Martres, M. P., Mayerova, A., Uyanik, G., Burgert, E., Duval, F., Macher, J. P., Javoy-Agid, F., Tamminga, C. A., Schwartz, J. C. and Sokoloff, P. (1996) Dopamine D3 receptor gene: organization, transcript variants and polymorphism associated with schizophrenia. Am. J. Med. Genet., 67: 58-70. [PMID:8678117]

36. Herroelen, L., De Backer, J. P., Wilczak, N., Flamez, A., Vauquelin, G. and De Keyser, J. (1994) Autoradiographic distribution of D3-type dopamine receptors in human brain using [3H]7-hydroxy-N,N-di-n-propyl-2-aminotetralin. Brain Res, 648: 222-228. [PMID:7922537]

37. Joseph, J. D., Wang, Y. M., Miles, P. R., Budygin, E. A., Picetti, R., Gainetdinov, R. R., Caron, M. G. and Wightman, R. M. (2002) Dopamine autoreceptor regulation of release and uptake in mouse brain slices in the absence of D(3) receptors. Neuroscience, 112: 39-49. [PMID:12044470]

38. Kagaya, T., Yonaga, M., Furuya, Y., Hashimoto, T., Kuroki, J. and Nishizawa, Y. (1996) Dopamine D3 agonists disrupt social behavior in rats. Brain Res, 721: 229-232. [PMID:8793104]

39. Kennedy, J. L., Billett, E. A., Macciardi, F. M., Verga, M., Parsons, T. J., Meltzer, H. Y., Lieberman, J. and Buchanan, J. A. (1995) Association study of dopamine D3 receptor gene and schizophrenia. Am J Med Genet, 60: 558-562. [PMID:8825896]

40. Khroyan, T. V., Baker, D. A. and Neisewander, J. L. (1995) Dose-dependent effects of the D3-preferring agonist 7-OH-DPAT on motor behaviors and place conditioning. Psychopharmacology (Berl), 122: 351-357. [PMID:8657832]

41. Kling-Petersen, T., Ljung, E. and Svensson, K. (1994) The preferential dopamine autoreceptor antagonist (+)-UH232 antagonizes the positive reinforcing effects of cocaine and d-amphetamine in the ICSS paradigm. Pharmacol Biochem Behav, 49: 345-351. [PMID:7824548]

42. Kling-Petersen, T., Ljung, E. and Svensson, K. (1995) Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J Neural Transm Gen Sect, 102: 209-220. [PMID:8788069]

43. Koeltzow, T., Cooper, D. C., Hu, X.-T., Xu, M., Tonegawa, S. and White, F. J. (1995) In vivo effects of dopaminergic ligands on dopamine D3 receptor deficient mice. (Abstract) Soc. Neurosci. Abst., 21: 364-.

44. Kreiss, D. S., Bergstrom, D. A., Gonzalez, A. M., Huang, K. X., Sibley, D. R. and Walters, J. R. (1995) Dopamine receptor agonist potencies for inhibition of cell firing correlate with dopamine D3 receptor binding affinities. Eur J Pharmacol, 277: 209-214. [PMID:7493610]

45. Kurashima, M., Yamada, K., Nagashima, M., Shirakawa, K. and Furukawa, T. (1995) Effects of putative dopamine D3 receptor agonists, 7-OH-DPAT, and quinpirole, on yawning, stereotypy, and body temperature in rats. Pharmacol Biochem Behav, 52: 503-508. [PMID:8545466]

46. Lahti, R. A., Roberts, R. C. and Tamminga, C. A. (1995) D2-family receptor distribution in human postmortem tissue: an autoradiographic study. Neuroreport, 6: 2505-2512. [PMID:8741751]

47. Landwehrmeyer, B., Mengod, G. and Palacios, J. M. (1993) Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res Mol Brain Res, 18: 187-192. [PMID:8097550]

48. Landwehrmeyer, B., Mengod, G. and Palacios, J. M. (1993) Differential visualization of dopamine D2 and D3 receptor sites in rat brain. A comparative study using in situ hybridization histochemistry and ligand binding autoradiography. Eur J Neurosci, 5: 145-153. [PMID:8261096]

49. Lannfelt, L., Sokoloff, P., Martres, M.P., Pilon, C., Giros, B., Jonsson, E., Sedvall, G. and Schwartz, J.C. (1992) Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr. Genet., 2: 249-256.

50. Le Foll, B., Diaz, J. and Sokoloff, P. (2005) Neuroadaptations to hyperdopaminergia in dopamine D3 receptor-deficient mice. Life Sci, 76: 1281-1296. [PMID:15642598]

51. Lejeune, F. and Millan, M. J. (1995) Activation of dopamine D3 autoreceptors inhibits firing of ventral tegmental dopaminergic neurones in vivo. Eur J Pharmacol, 275: R7-R9. [PMID:7768288]

52. Levant, B. and Vansell, N. R. (1997) In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology, 17: 67-71. [PMID:9252981]

53. Levant, B., Grigoriadis, D. E. and DeSouza, E. B. (1992) Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain. J Pharmacol Exp Ther, 262: 929-935. [PMID:1356154]

54. Liu, J. C., Cox, R. F., Greif, G. J., Freedman, J. E. and Waszczak, B. L. (1994) The putative dopamine D3 receptor agonist 7-OH-DPAT: lack of mesolimbic selectivity. Eur J Pharmacol, 264: 269-278. [PMID:7698165]

55. Liu, L. X., Monsma, F. J., Sibley, D. R. and Chiodo, L. A. (1996) D2L, D2S, and D3 dopamine receptors stably transfected into NG108-15 cells couple to a voltage-dependent potassium current via distinct G protein mechanisms. Synapse, 24: 156-164. [PMID:8890457]

56. Lévesque, D., Diaz, J., Pilon, C., Martres, M. P., Giros, B., Souil, E., Schott, D., Morgat, J. L., Schwartz, J. C. and Sokoloff, P. (1992) Identification, characterization, and localization of the dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin. Proc Natl Acad Sci U S A, 89: 8155-8159. [PMID:1518841]

57. MacKenzie, R. G., VanLeeuwen, D., Pugsley, T. A., Shih, Y. H., Demattos, S., Tang, L., Todd, R. D. and O'Malley, K. L. (1994) Characterization of the human dopamine D3 receptor expressed in transfected cell lines. Eur J Pharmacol, 266: 79-85. [PMID:7907989]

58. Maggio, R., Scarselli, M., Novi, F., Millan, M. J. and Corsini, G. U. (2003) Potent activation of dopamine D3/D2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem, 87: 631-641. [PMID:14535946]

59. Malmberg, A., Jackson, D. M., Eriksson, A. and Mohell, N. (1993) Unique binding characteristics of antipsychotic agents interacting with human dopamine D2A, D2B, and D3 receptors. Mol Pharmacol, 43: 749-754. [PMID:8099194]

60. Mant, R., Williams, J., Asherson, P., Parfitt, E., McGuffin, P. and Owen, M. J. (1994) Relationship between homozygosity at the dopamine D3 receptor gene and schizophrenia. Am J Med Genet, 54: 21-26. [PMID:7909989]

61. McAllister, G., Knowles, M. R., Ward-Booth, S. M., Sinclair, H. A., Patel, S., Marwood, R., Emms, F., Patel, S., Smith, A. and Seabrook, G. R. (1995) Functional coupling of human D2, D3, and D4 dopamine receptors in HEK293 cells. J Recept Signal Transduct Res, 15: 267-281. [PMID:8903944]

62. McElroy, J., Zeller, K. L., Amy, K. A., Ward, K. A., Cawley, J. F., Mazzola, A. L., Keim, W. and Rohrbach, K. (1993) In vivo agonist properties of 7-hydroxy-N,N-Di-N-propyl-2-aminotetralin, a dopamine D3-selective receptor ligand. Drug Development Research, 30: 257-259.

63. McQuade, J. A., Benoit, S. C., Xu, M., Woods, S. C. and Seeley, R. J. (2004) High-fat diet induced adiposity in mice with targeted disruption of the dopamine-3 receptor gene. Behav Brain Res, 151: 313-319. [PMID:15084447]

64. Mierau, J., Schneider, F. J., Ensinger, H. A., Chio, C. L., Lajiness, M. E. and Huff, R. M. (1995) Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur J Pharmacol, 290: 29-36. [PMID:7664822]

65. Millan, M. J., Audinot, V., Melon, C. and Newman-Tancredi, A. (1995) Evidence that dopamine D3 receptors participate in clozapine-induced hypothermia. Eur J Pharmacol, 280: 225-229. [PMID:7589191]

66. Millan, M. J., Audinot, V., Rivet, J. M., Gobert, A., Vian, J., Prost, J. F., Spedding, M. and Peglion, J. L. (1994) S 14297, a novel selective ligand at cloned human dopamine D3 receptors, blocks 7-OH-DPAT-induced hypothermia in rats. Eur J Pharmacol, 260: R3-R5. [PMID:7988633]

67. Millan, M. J., Gobert, A., Newman-Tancredi, A., Lejeune, F., Cussac, D., Rivet, J. M., Audinot, V., Dubuffet, T. and Lavielle, G. (2000) S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther, 293: 1048-1062. [PMID:10869410]

68. Millan, M. J., Maiofiss, L., Cussac, D., Audinot, V., Boutin, J. A. and Newman-Tancredi, A. (2002) Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther, 303: 791-804. [PMID:12388666]

69. Millan, M. J., Peglion, J. L., Vian, J., Rivet, J. M., Brocco, M., Gobert, A., Newman-Tancredi, A., Dacquet, C., Bervoets, K. and Girardon, S. (1995) Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy. J Pharmacol Exp Ther, 275: 885-898. [PMID:7473180]

70. Mizuo, K., Narita, M., Miyatake, M. and Suzuki, T. (2004) Enhancement of dopamine-induced signaling responses in the forebrain of mice lacking dopamine D3 receptor. Neurosci Lett, 358: 13-16. [PMID:15016423]

71. Narita, M., Mizuo, K., Mizoguchi, H., Sakata, M., Narita, M., Tseng, L. F. and Suzuki, T. (2003) Molecular evidence for the functional role of dopamine D3 receptor in the morphine-induced rewarding effect and hyperlocomotion. J Neurosci, 23: 1006-1012. [PMID:12574430]

72. Narita, M., Soma, M., Tamaki, H., Narita, M. and Suzuki, T. (2002) Intensification of the development of ethanol dependence in mice lacking dopamine D(3) receptor. Neurosci Lett, 324: 129-132. [PMID:11988344]

73. O'hara, C. M., Uhland-Smith, A., O'Malley, K. L. and Todd, R. D. (1996) Inhibition of dopamine synthesis by dopamine D2 and D3 but not D4 receptors. J Pharmacol Exp Ther, 277: 186-192. [PMID:8613917]

74. Parsian, A., Chakraverty, S. and Todd, R. D. (1995) Possible association between the dopamine D3 receptor gene and bipolar affective disorder. Am J Med Genet, 60: 234-237. [PMID:7573178]

75. Parsons, B., Stanley, M. and Javitch, J. (1993) Differential visualization of dopamine D2 and D3 receptors in rat brain. Eur J Pharmacol, 234: 269-272. [PMID:8097723]

76. Perachon, S., Betancur, C., Pilon, C., Rostene, W., Schwartz, J. C. and Sokoloff, P. (2000) Role of dopamine D3 receptors in thermoregulation: a reappraisal. Neuroreport, 11: 221-225. [PMID:10683862]

77. Pilon, C., Lévesque, D., Dimitriadou, V., Griffon, N., Martres, M. P., Schwartz, J. C. and Sokoloff, P. (1994) Functional coupling of the human dopamine D3 receptor in a transfected NG 108-15 neuroblastoma-glioma hybrid cell line. Eur J Pharmacol, 268: 129-139. [PMID:7957635]

78. Potenza, M. N., Graminski, G. F., Schmauss, C. and Lerner, M. R. (1994) Functional expression and characterization of human D2 and D3 dopamine receptors. J Neurosci, 14: 1463-1476. [PMID:7907363]

79. Pugsley, T. A., Davis, M. D., Akunne, H. C., MacKenzie, R. G., Shih, Y. H., Damsma, G., Wikstrom, H., Whetzel, S. Z., Georgic, L. M. and Cooke, L. W. (1995) Neurochemical and functional characterization of the preferentially selective dopamine D3 agonist PD 128907. J Pharmacol Exp Ther, 275: 1355-1366. [PMID:8531103]

80. Reavill, C., Taylor, S. G., Wood, M. D., Ashmeade, T., Austin, N. E., Avenell, K. Y., Boyfield, I., Branch, C. L., Cilia, J., Coldwell, M. C., Hadley, M. S., Hunter, A. J., Jeffrey, P., Jewitt, F., Johnson, C. N., Jones, D. N., Medhurst, A. D., Middlemiss, D. N., Nash, D. J., Riley, G. J., Routledge, C., Stemp, G., Thewlis, K. M., Trail, B., Vong, A. K. and Hagan, J. J. (2000) Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J Pharmacol Exp Ther, 294: 1154-1165. [PMID:10945872]

81. Ricci, A., Vega, J. A., Mammola, C. L. and Amenta, F. (1995) Localisation of dopamine D3 receptor in the rat cerebellar cortex: a light microscope autoradiographic study. Neurosci Lett, 190: 163-166. [PMID:7637884]

82. Ricci, A; Veglio, F; Amenta, F. (1995) Radioligand binding characterization of putative dopamine D3 receptor in human peripheral blood lymphocytes with [3H]7-OH-DPAT. J. Neuroimmunol., 58 (2): 139-44. [PMID:7759603]

83. Rivet, J. M., Audinot, V., Gobert, A., Peglion, J. L. and Millan, M. J. (1994) Modulation of mesolimbic dopamine release by the selective dopamine D3 receptor antagonist, (+)-S 14297. Eur J Pharmacol, 265: 175-177. [PMID:7875234]

84. Sanger, D. J., Depoortere, R. and Perrault, G. (1996) Evidence for a role for dopamine D3 receptors in the effects of dopamine agonists on operant behaviour in rats. Behav Pharmacol, 7: 477-482. [PMID:11224444]

85. Sautel, F., Griffon, N., Lévesque, D., Pilon, C., Schwartz, J. C. and Sokoloff, P. (1995) A functional test identifies dopamine agonists selective for D3versus D2receptors. Neuroreport, 6: 329-332. [PMID:7756621]

86. Sautel, F., Griffon, N., Sokoloff, P., Schwartz, J. C., Launay, C., Simon, P., Costentin, J., Schoenfelder, A., Garrido, F., Mann, A. et al.. (1995) Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J. Pharmacol. Exp. Ther., 275: 1239-1246. [PMID:8531087]

87. Schmauss, C., Haroutunian, V., Davis, K. L. and Davidson, M. (1993) Selective loss of dopamine D3-type receptor mRNA expression in parietal and motor cortices of patients with chronic schizophrenia. Proc. Natl. Acad. Sci. U.S.A., 90: 8942-8946. [PMID:8415635]

88. Seabrook, G. R., Patel, S., Marwood, R., Emms, F., Knowles, M. R., Freedman, S. B. and McAllister, G. (1992) Stable expression of human D3 dopamine receptors in GH4C1 pituitary cells. FEBS Lett, 312: 123-126. [PMID:1330688]

89. Skaaning Jensen, B., Levavi-Sivan, B., Fishburn, C. S. and Fuchs, S. (1997) Functional expression of the murine D2, D3, and D4 dopamine receptors in Xenopus laevis oocytes. FEBS Lett, 420: 191-195. [PMID:9459308]

90. Sokoloff, P., Andrieux, M., Besançon, R., Pilon, C., Martres, M.-P., Giros, B. and Schwartz, J.-C. (1992) Pharmacology of human D3 dopamine receptor expressed in a mammalian cell line : comparison with D2 receptor. Eur. J. Pharmacol., 225: 331-337. [PMID:1354163]

91. Sokoloff, P., Giros, B., Martres, M. P., Bouthenet, M. L. and Schwartz, J. C. (1990) Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature, 347: 146-151. [PMID:1975644]

92. Song, R; Zhang, HY; Li, X; Bi, GH; Gardner, EL; Xi, ZX. (2012) Increased vulnerability to cocaine in mice lacking dopamine D3 receptors. Proc. Natl. Acad. Sci. U.S.A., 109 (43): 17675-80. [PMID:23045656]

93. Starr, M. S. and Starr, B. S. (1995) Motor actions of 7-OH-DPAT in normal and reserpine-treated mice suggest involvement of both dopamine D2 and D3 receptors. Eur J Pharmacol, 277: 151-158. [PMID:7493603]

94. Steiner, H., Fuchs, S. and Accili, D. (1997) D3 dopamine receptor-deficient mouse: evidence for reduced anxiety. Physiol Behav, 63: 137-141. [PMID:9402626]

95. Svensson, K., Carlsson, A. and Waters, N. (1994) Locomotor inhibition by the D3 ligand R-(+)-7-OH-DPAT is independent of changes in dopamine release. J Neural Transm Gen Sect, 95: 71-74. [PMID:7857588]

96. Svensson, K., Carlsson, A., Huff, R. M., Kling-Petersen, T. and Waters, N. (1994) Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors. Eur J Pharmacol, 263: 235-243. [PMID:7843260]

97. Tang, L., Todd, R. D. and O'Malley, K. L. (1994) Dopamine D2 and D3 receptors inhibit dopamine release. J Pharmacol Exp Ther, 270: 475-479. [PMID:8071839]

98. Tang, L., Todd, R. D., Heller, A. and O'Malley, K. L. (1994) Pharmacological and functional characterization of D2, D3 and D4 dopamine receptors in fibroblast and dopaminergic cell lines. J Pharmacol Exp Ther, 268: 495-502. [PMID:8301592]

99. Waters, N., Löfberg, L., Haadsma-Svensson, S., Svensson, K., Sonesson, C. and Carlsson, A. (1994) Differential effects of dopamine D2 and D3 receptor antagonists in regard to dopamine release, in vivo receptor displacement and behaviour. J Neural Transm Gen Sect, 98: 39-55. [PMID:7710738]

100. Waters, N., Svensson, K., Haadsma-Svensson, S. R., Smith, M. W. and Carlsson, A. (1993) The dopamine D3 receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J. Neural Transm. Gen. Sect., 94: 11-19. [PMID:8129881]

101. Werner, P., Hussy, N., Buell, G., Jones, K. A. and North, R. A. (1996) D2, D3, and D4 dopamine receptors couple to G protein-regulated potassium channels in Xenopus oocytes. Mol Pharmacol, 49: 656-661. [PMID:8609893]

102. Xu, M., Caine, S. B., Cooper, D. C., Gold, L. H., Graybiel, A. M., Hu, X. T., Loeltzow, T., Koob, G. F., Moratalla, R., White, F. J. and Tonegawa, S. (1995) Analysis of dopamine D3 and D1 receptor mutant mice. (Abstract) Soc. Neurosci. Abst., 21: 363-.

103. Xu, M., Koeltzow, T. E., Santiago, G. T., Moratalla, R., Cooper, D. C., Hu, X. T., White, N. M., Graybiel, A. M., White, F. J. and Tonegawa, S. (1997) Dopamine D3 receptor mutant mice exhibit increased behavioral sensitivity to concurrent stimulation of D1 and D2 receptors. Neuron, 79: 837-848. [PMID:9354330]

104. Yamada, S., Yokoo, H. and Nishi, S. (1994) Differential effects of dopamine agonists on evoked dopamine release from slices of striatum and nucleus accumbens in rats. Brain Res, 648: 176-179. [PMID:7922522]

105. Zhen, J; Antonio, T; Dutta, AK; Reith, ME. (2010) Concentration of receptor and ligand revisited in a modified receptor binding protocol for high-affinity radioligands: [3H]Spiperone binding to D2 and D3 dopamine receptors. J. Neurosci. Methods, 188 (1): 32-8. [PMID:20122961]

To cite this database page, please use the following:

Arvid Carlsson, Marc Caron, Olivier Civelli, John W. Kebabian, Saloman Z. Langer, Bernard Scatton, Jean-Charles Schwartz, Goran Sedvall, Philip Seeman, Pierre Sokoloff, Pierre F. Spano, Hubert H. M. Van Tol.
Dopamine receptors: D3 receptor. Last modified on 08/03/2013. Accessed on 21/05/2013. IUPHAR database (IUPHAR-DB), http://www.iuphar-db.org/DATABASE/ObjectDisplayForward?objectId=216.


Contact us | Print | Back to top | Help